Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor- blinded phase IV study (IMMpulse)

Authors
Category Primary study
JournalBRITISH JOURNAL OF DERMATOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 31db3f95c66e5c843eb7bd2d433e645014108374
First added on: Dec 05, 2023